FIELD: medicine; oncology.
SUBSTANCE: present group of inventions refers to cancer treatment. For this purpose, a combination of drugs is introduced, including (6S,9aS)-N-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluorine-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide and anti-PD-1 antibody.
EFFECT: introduction of such combination provides effective cancer treatment, including in patients with low sensitivity to monotherapy with an immune control point inhibitor.
2 cl, 5 dwg, 1 tbl, 4 ex
| Title |
Year |
Author |
Number |
| ALPHA-SPIRAL MIMETICS AND METHODS ASSOCIATED WITH THEM |
2009 |
- Odagami Takenao
- Kogami Judzi
- Koudzi Khirojuki
|
RU2512538C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION |
2016 |
- Mehta, Vimal D.
- Rastelli, Luca
- Sapra, Aparna Katoch
|
RU2817047C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS |
2019 |
- Li, Shijie
- Mali, Venkat Reddy
- Singh, Rajinder
- Yang, Ju
- Zhang, Penglie
|
RU2810717C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS |
2017 |
- Kezada, Serkhio
- Peggs, Karl
- Arse Vargas, Frederik
|
RU2759970C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION |
2016 |
- Mehta, Vimal D.
- Rastelli, Luca
- Sapra, Aparna Katoch
|
RU2711380C2 |
| CRYSTAL (6S,9AS)-N-BENZYL-8-({6-[3-(4-ETHYLPIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN-2-YL}METHYL)-6-(2-FLUORINE-4-HYDROXYBENZYL)-4,7-DIOXO-2-(PROP-2-EN-1-YL)HEXAHYDRO-2H-PYRAZINO[2,1-C][1,2,4]TRIAZINE-1(6H)-CARBOXAMIDE |
2016 |
|
RU2723551C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY |
2017 |
|
RU2755903C2 |
| COMBINATION CONTAINING MULTIFUNCTIONAL ANTIBODIES REDIRECTING T-CELLS AND CONTROL POINT MODULATORS, AND ITS APPLICATIONS |
2017 |
|
RU2773655C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS |
2017 |
- Sharo Izrael
- Chon Khejyun
- Shall Tomas Dzh.
- Chzhan Penli
|
RU2745195C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR |
2018 |
|
RU2740713C1 |
